Successful treatment of metastatic breast tumor using ribociclib in combination with hormonal therapy – case report
2023
Abstract
Metastatic hormone-dependent breast cancer treatment has undergone significant changes in recent years. In addition to hormone therapy, which is still the cornerstone of treatment in most cases, targeted therapy in the form of a CDK4/6 inhibitor has been added to the combination.
Currently, three different CDK4/6 inhibitors are available. The following case report demonstrates the therapeutic effect of combining an aromatase inhibitor with ribociclib, which achieved a long-lasting therapeutic effect.